Wednesday, February 10, 2016 7:27:49 AM
CytoSorb in a case of caecum perforation and fecal 4-quadrant peritonitis
Friedrich Nestler, Hospital Erlabrunn
Summary:
This case study reports on a 76-year-old male patient who underwent emergency laparotomy due to an acute abdomen after a previous total hip replacement surgery.
Case presentation
Intraoperatively confirmed colon perforation with 4 quadrant fecal peritonitis
On admission to ICU after preceeding surgery the patient was in septic shock with need for high catecholamine doses and mechanical ventilation
Due to concomitant onset of renal failure with highly elevated inflammatory and infection markers (leucocytes 18.3, PCT 14.2, IL-6 5000, CRP 459), the patient was started on renal replacement therapy in combination with CytoSorb
Treatment
Three consecutive CytoSorb treatment sessions of 24 hours each over a total period of 72 hours
Cytosorb was used in conjunction with CRRT (Baxter BM11a/BM14) in CVVHF mode
Blood flow rate: 140 ml/min
Anticoagulation: citrate
CytoSorb adsorber position: pre-hemofilter
Measurements
IL-6, PCT, CRP, leucocytes
Demand for catecholamines
Renal function (diuresis, creatinine, urea)
Results
Hemodynamic stabilization of the patient with significantly decreased needs for catecholamines
Effective reduction of IL-6 levels down to 200 pg/ml after the last treatment
Declining plasma levels of CRP and PCT during the three CytoSorb sessions
Marked improvement of renal function with onset of spontaneous diuresis and decreasing retention parameters
Patient Follow-Up
In the further course secondary wound infection with local abdominal wall infection, requiring intraabdominal lavage, debridement and ultimately secondary abdominal wall closure
Delayed weaning, critical illness polyneuropathy
Successful transfer of the patient to a neurologic rehabilitation unit in the further course
Conclusions
Treatment with CytoSorb resulted in a significant stabilization of hemodynamics with declining needs for catecholamines, an effective reduction of inflammatory markers as well as a considerable improvement of kidney function
Handling of the absorber was safe and easy after an initial training phase
http://cytosorb-therapy.com/
Recent CTSO News
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
- CytoSorbents to Report Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 10/27/2023 11:00:00 AM
- CytoSorbents to Present at the 8th Annual Dawson James Conference • GlobeNewswire Inc. • 10/05/2023 11:00:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM